Style | Citing Format |
---|---|
MLA | Sheibani M, et al.. "Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-Clinical Therapeutic Approaches." Cardiovascular Toxicology, vol. 22, no. 4, 2022, pp. 292-310. |
APA | Sheibani M, Azizi Y, Shayan M, Nezamoleslami S, Eslami F, Farjoo MH, Dehpour AR (2022). Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-Clinical Therapeutic Approaches. Cardiovascular Toxicology, 22(4), 292-310. |
Chicago | Sheibani M, Azizi Y, Shayan M, Nezamoleslami S, Eslami F, Farjoo MH, Dehpour AR. "Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-Clinical Therapeutic Approaches." Cardiovascular Toxicology 22, no. 4 (2022): 292-310. |
Harvard | Sheibani M et al. (2022) 'Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-Clinical Therapeutic Approaches', Cardiovascular Toxicology, 22(4), pp. 292-310. |
Vancouver | Sheibani M, Azizi Y, Shayan M, Nezamoleslami S, Eslami F, Farjoo MH, et al.. Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-Clinical Therapeutic Approaches. Cardiovascular Toxicology. 2022;22(4):292-310. |
BibTex | @article{ author = {Sheibani M and Azizi Y and Shayan M and Nezamoleslami S and Eslami F and Farjoo MH and Dehpour AR}, title = {Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-Clinical Therapeutic Approaches}, journal = {Cardiovascular Toxicology}, volume = {22}, number = {4}, pages = {292-310}, year = {2022} } |
RIS | TY - JOUR AU - Sheibani M AU - Azizi Y AU - Shayan M AU - Nezamoleslami S AU - Eslami F AU - Farjoo MH AU - Dehpour AR TI - Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-Clinical Therapeutic Approaches JO - Cardiovascular Toxicology VL - 22 IS - 4 SP - 292 EP - 310 PY - 2022 ER - |